4 Results for "

ectopic bone.

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "ectopic bone." in MCE Product Catalog:

Cat. No.: HY-P5832
CAS No.: 836606-84-9
Target:  

TGF-beta/Smad RUNX

Domaines de recherche:  

Metabolic Disease

BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research .
loading...
    loading...
Cat. No.: HY-171249
CAS No.: 3034216-31-1
Target:  

TGF-β Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology

CDD-1431 is a low-nanomolar selective kinase inhibitors of BMPR2, with Kiapp value of 20.6 nM. CDD-1431 suppresses BRE-reporter activity, with an IC50 of 4.87 μM. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation .
loading...
    loading...
Cat. No.: HY-L131
950 compounds

Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.

Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.

MCE offers a unique collection of 950 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

Cat. No.: HY-159978
CAS No.: 1628848-73-6
Synonyms: EOS789
Atidafonat is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. Atidafonat inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. Atidafonat ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. Atidafonat can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) .
loading...
    loading...